Temporal Trends of Acute Hepatitis A in Brazil and Its Regions
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
Citação
VIRUSES-BASEL, v.14, n.12, article ID 2737, 8p, 2022
Resumo
Background: Hepatitis A is responsible for 126,000,000 cases of acute viral hepatitis distributed heterogeneously worldwide, with a high disability-adjusted life year (DALY) rate, especially in low-income countries. Data related to Hepatitis A provides information to improve control measures and identify the population at risk. This study aims to analyze temporal trends of Hepatitis A in Brazil and its regions from 2007 to 2018, based on official notification data. Methods: Data related to Hepatitis A reported cases from 2007 to 2018 were fitted to a joinpoint model by Brazilian regions, age groups, and gender, allowing the calculation of average annual percentage change (AAPC) and annual percentage change (APC) to estimate trends of Hepatitis A in Brazil. Findings: From 2007 to 2018, 65,284 Hepatitis A cases notified in Brazil were available for analysis. The Northeast Region reported 18,732 (28.69%) cases, followed by the North Region reporting 18,430 (28.23%), the Southeast Region reporting 14,073 (21.55%), the South Region reporting 7909 (12.11%), and the Central-West Region reporting 6140 (9.4%), respectively. Temporal trend analysis showed that Hepatitis A incidence decreased from 2007 to 2016 in all Brazilian regions for individuals less than 20 years old, but increased in the South and Southeast males between 20 to 39 years after 2016. Conclusions: Hepatitis A endemicity is heterogeneous among Brazilian regions. In addition, an unexpected outbreak of HAV among Southeast and South adult males in 2016 resembles the outbreak in Europe, revealing a vulnerable population that should be prioritized by vaccination programs and control measures.
Palavras-chave
Hepatitis A, Hepatitis A virus, epidemiology, mathematical modelling, trends
Referências
- Andani A, 2020, EXPERT REV VACCINES, V19, P795, DOI 10.1080/14760584.2020.1813575
- Bierrenbach AL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040407
- Brito Wagner Izidoro de, 2020, Rev. bras. epidemiol., V23, pe200073, DOI 10.1590/1980-549720200073
- Chuffi S, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14010073
- Clegg LX, 2009, STAT MED, V28, P3670, DOI 10.1002/sim.3733
- Ximenes RAD, 2008, INT J EPIDEMIOL, V37, P852, DOI 10.1093/ije/dyn114
- De Oliveira TM, 2020, J MED VIROL, V92, P1343, DOI 10.1002/jmv.25694
- Fares Auda, 2015, J Family Med Prim Care, V4, P96, DOI 10.4103/2249-4863.152263
- Hanafiah KM, 2011, INT J HEALTH GEOGR, V10, DOI 10.1186/1476-072X-10-57
- IBGE, US
- Li YS, 2022, BMC INFECT DIS, V22, DOI 10.1186/s12879-022-07651-5
- Mariojoules J, 2019, J CLIN VIROL, V117, P49, DOI 10.1016/j.jcv.2019.05.014
- Mello VM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030281
- Ministerio da Saude, 2015, MAN OP SINAN VERS
- Ministerio da Saude Protocolo, 2020, CLIN DIR TER AT PESS
- Ministerio da Saude Vacina de Hepatite, 2013, A REL REC COM NAC IN
- Ministerio do Desenvolvimento Regional Diagnostico dos Servicos, 2017, DIAGN SERV AG ESG 2
- Ndumbi P, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.33.1700641
- Pereira LMMB, 2021, REV INST MED TROP SP, V63, DOI [10.1590/S1678-9946202163034, 10.1590/s1678-9946202163034]
- Sachdeva H, 2019, Can Commun Dis Rep, V45, P262, DOI 10.14745/ccdr.v45i10a03
- Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7
- VILLAR Livia Melo, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P289, DOI 10.1590/S0036-46652002000500011
- World Health Organization, 2022, GLOB PREV HEP VIR IN
- World Health Organization, 2012, WHO POS PAP HEP VACC
- World Health Organization (WHO), 2021, DEPRESSION
- Zeng DY, 2021, J HEPATOL, V75, P547, DOI 10.1016/j.jhep.2021.04.035
- Zou J., 2009, AAPC JOINPOINT CONNE, V1